Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Swedish Orphan Biovitrum AB ( (SE:SOBI) ) is now available.
Sobi reported accelerated growth in Q3 2025, with a 21% increase in revenue at constant exchange rates, driven by strong performance in its haematology and immunology segments. The company highlighted significant progress in its strategic portfolio, including the US filing acceptance for NASP in uncontrolled gout and EU approval for Tryngolza in severe hypertriglyceridemia. Despite a substantial impairment charge for Vonjo, Sobi remains optimistic about its long-term growth potential, with several new product launches anticipated to further strengthen its market position.
The most recent analyst rating on (SE:SOBI) stock is a Buy with a SEK370.00 price target. To see the full list of analyst forecasts on Swedish Orphan Biovitrum AB stock, see the SE:SOBI Stock Forecast page.
More about Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB (Sobi) operates in the biopharmaceutical industry, focusing on developing and delivering innovative therapies for rare diseases. The company primarily offers products in haematology and immunology, with a strategic emphasis on expanding its portfolio to address unmet medical needs in these areas.
YTD Price Performance: -1.83%
Average Trading Volume: 313,488
Technical Sentiment Signal: Strong Buy
Current Market Cap: SEK107.5B
See more data about SOBI stock on TipRanks’ Stock Analysis page.